Ginkgo Bioworks is expanding its original research partnership with Novo Nordisk to cover the entire value chain.
The new pact is a “flexible and scalable” new model, the companies said in a Wednesday release. “We’ve created something where it’ll help Novo to start doing a variety of projects faster,” Aaron Schwartz, Ginkgo’s senior director of business development in biotech and pharma, told Endpoints News in an interview.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.